Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 9.54 USD -1.95% Market Closed
Market Cap: 520.9m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

STOK Price Targets Summary
Stoke Therapeutics Inc

Wall Street analysts forecast STOK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for STOK is 24.35 USD with a low forecast of 15.15 USD and a high forecast of 49.35 USD.

STOK Lowest Forecast
Wall Street Target
15.15 USD
59% Upside
STOK Average Forecast
Wall Street Target
24.35 USD
155% Upside
STOK Highest Forecast
Wall Street Target
49.35 USD
417% Upside
Lowest
Price Target
15.15 USD
59% Upside
Average
Price Target
24.35 USD
155% Upside
Highest
Price Target
49.35 USD
417% Upside
Stoke Therapeutics Inc Competitors:
Price Targets
300122
Chongqing Zhifei Biological Products Co Ltd
57% Upside
2616
CStone Pharmaceuticals
29% Downside
C
2487
Cutia Therapeutics
14% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
31% Upside
300122
Chongqing Zhifei Biological Products Co Ltd
57% Upside
2616
CStone Pharmaceuticals
29% Downside
C
2487
Cutia Therapeutics
14% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
31% Upside
EXEL
Exelixis Inc
10% Downside
MDXG
MiMedx Group Inc
90% Upside
BEAM
Beam Therapeutics Inc
211% Upside
ALDX
Aldeyra Therapeutics Inc
293% Upside

Revenue
Forecast

Revenue Estimate
Stoke Therapeutics Inc

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 25%.

N/A
Past Growth
25%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Stoke Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

See Also

Summary
STOK intrinsic value, competitors valuation, and company profile.
DCF Valuation
STOK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
STOK stock valuation using valuation multiples.
Wall Street Estimates
STOK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
STOK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is STOK's stock price target?
Price Target
24.35 USD

According to Wall Street analysts, the average 1-year price target for STOK is 24.35 USD with a low forecast of 15.15 USD and a high forecast of 49.35 USD.

What is Stoke Therapeutics Inc's Revenue forecast?
Projected CAGR
25%

The compound annual growth rate of Stoke Therapeutics Inc's revenue for the next 3 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.